Hatz K, et al. - This study was aimed to gauge the dexamethasone intravitreal implant 0.7 mg (DEX implant) in the treatment of diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (anti-VEGF) therapy. Authors also assessed the predictive factors. In patients with DME refractory to anti-VEGF therapy, repeated intravitreal DEX injections with average intervals of 4 months were seen to be valuable. If evaluated after an initial reduction of macular edema, disorganization of outer retinal layers (EZ-ELM) could predict smaller visual acuity (VA) gains.